Inspire Medical Systems Inc

Inspire Medical Systems Inc(INSP)の株式分析

$71.110

-1.515 (-2.13%)終値時点

Loading chart…
高値
72.750
始値
72.250
出来高加重平均価格
70.77
出来高
592.14K
時価総額
4.02B
安値
68.439
売買代金
41.90M
EV/EBITDA(TTM)
134.37

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.

www.inspiresleep.com

AI分析 of Inspire Medical Systems Inc (INSP)

買い

Inspire Medical Systems Inc (INSP) is a good buy right now due to its current price of $71.11, which is below several analyst price targets indicating potential upside. Notably, Freedom Broker's target of $97 suggests a 36.4% upside from the current price. Additionally, the company reported a gross margin of 86.47% for Q1 2026, indicating strong profitability. However, the forward P/E ratio of 59.17 suggests that the stock may be overvalued if growth does not materialize as expected, representing a key risk.

アナリスト評価(5)

上値余地 +104.35%
買い
3 買い
2 中立
0 売り
現在: 71.11
安値
91.00
平均
145.31
高値
180.00

RBC Capital

2026-10-01

目標株価

$75

Sector Perform

Freedom Broker

2026-09-21

目標株価

$97

買い

Stifel

2026-09-11

目標株価

$80

買い

Mizuho

2026-08-04

目標株価

$65

アウトパフォーム

JPMorgan

2026-08-04

目標株価

$60

中立

バリュエーション指標

Inspire Medical Systems Inc(INSP)の現在の予想PERは59.17で、5年平均は48.04です。

予想PER

適正
5年平均 P/E
48.04
現在のP/E
59.17
割高
298.22
割安
-202.13

予想EV/EBITDA

適正
5年平均 EV/EBITDA
5.20
現在のEV/EBITDA
134.37
割高
174.51
割安
-164.11

予想PSR

割安
5年平均 P/S
8.23
現在のP/S
2.37
割高
13.72
割安
2.74

Alphio AI による INSP の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%INSP

$195.33

シナリオ価格

基

基本

基本 · 50%INSP

$174.83

シナリオ価格

弱

弱気

弱気 · 25%INSP

$166.61

シナリオ価格

INSP を保有するクジラ

B

Braidwell LP

+ を保有INSP

+24.47%

3か月リターン

S

Soleus Capital Management, L.P.

+ を保有INSP

-6.31%

3か月リターン

D

Deerfield Management Company, L.P.

+ を保有INSP

-6.60%

3か月リターン

A

ADAR1 Capital Management, LLC

+ を保有INSP

-12.59%

3か月リターン

INSP のよくある質問 — Alphio AI が回答

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Inspire Medical Systems Inc (INSP) is a good buy right now due to its current price of $71.11, which is below several analyst price targets indicating potential upside. Notably, Freedom Broker's target of $97 suggests a 36.4% upside from the current price. Additionally, the company reported a gross margin of 86.47% for Q1 2026, indicating strong profitability. However, the forward P/E ratio of 59.17 suggests that the stock may be overvalued if growth does not materialize as expected, representing a key risk.

5 analysts cover INSP: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 145.31.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める